Cancer Family
Pleural Mesothelial Neoplasm
CI-CAN-00000322Explore in graph →
Non-malignant34 active trials4 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000322Explore in graph →
Clinical trials
157 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06790082 | The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma(FAPI-PM) | recruiting | Phase 2 | 70 | Aalborg University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT04525859 | Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma | completed | Phase 1 | 19 | Oncovir, Inc.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05188859 | First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma | recruiting | Phase 2 | 29 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04040231 | Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | completed | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT02649829 | Autologous Dendritic Cell Vaccination in Mesothelioma(MESODEC) | completed | Phase 1 / Phase 2 | 28 | University Hospital, AntwerpOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06910449 | Hemithoracic Arc Radiotherapy Post Pleural Decortication | recruiting | N/A | 45 | Cairo UniversityOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06886672 | Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS(MAGNETS) | recruiting | — | 60 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06726564 | A Study of MT027 in Patients with Pleural Malignant Tumors | recruiting | Phase 1 | 18 | Suzhou Maximum Bio-tech Co., Ltd.INDUSTRY | 1 | Dec 10, 2024 | clinicaltrials |
| NCT05228015 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | terminated | Phase 1 | 67 | Ikena OncologyINDUSTRY | 3 | Nov 18, 2024 | clinicaltrials |
| NCT04843007 | Alvopem® (Pemetrexed) Safety Assessment | completed | — | 199 | NanoAlvandINDUSTRY | 0 | Oct 23, 2024 | clinicaltrials |
| NCT01265433 | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy | completed | Phase 2 | 41 | Sellas Life Sciences GroupINDUSTRY | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05660616 | Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 40 | Ain Shams UniversityOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT02707666 | A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma | terminated | Phase 1 | 7 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04480372 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | completed | Phase 2 | 68 | Swiss Cancer InstituteOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06410625 | Evaluation of Response by FLT PET in Mesothelioma(FLT-MM) | unknown | N/A | 25 | Ankara UniversityOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06416930 | Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma | not yet recruiting | Phase 2 | 59 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT04324437 | eRAPID: Online Symptom Reporting in Lung Cancer | completed | N/A | 43 | University of LeedsOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05425576 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | not yet recruiting | Phase 2 | 63 | Oncotelic Inc.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05930665 | Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma | unknown | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants | terminated | Phase 2 | 35 | Verastem, Inc.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04823741 | Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma(SCITH-MESO) | unknown | — | 30 | Hospices Civils de LyonOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT06031636 | Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma | unknown | — | 15 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT01486368 | A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02899195 | Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma(PrE0505) | completed | Phase 2 | 55 | PrECOG, LLC.OTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05910112 | Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention(PROSPECT) | unknown | — | 2,000 | University of OxfordOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02414945 | TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients | completed | Phase 1 / Phase 2 | 9 | University Health Network, TorontoOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02555007 | Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM(NVB Metro) | completed | Phase 1 | 30 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02436733 | Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM | unknown | Phase 2 | 64 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Nov 7, 2022 | clinicaltrials |
| NCT00652574 | Dasatinib in Resectable Malignant Pleural Mesothelioma | completed | Phase 1 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT00738582 | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma(Amatuximab) | completed | Phase 2 | 89 | MorphotekINDUSTRY | 5 | Sep 22, 2022 | clinicaltrials |
| NCT01865045 | Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients | completed | — | 150 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05508555 | Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma | unknown | N/A | 50 | Ain Shams UniversityOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04013334 | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma | unknown | Phase 2 | 12 | Momotaro-Gene Inc.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04775446 | Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy(MESOIMMUNE) | completed | — | 116 | Centre Hospitalier Intercommunal CreteilOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT02568449 | Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05077111 | A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia(VATS) | unknown | Phase 4 | 40 | Mohamed Reda AshourOTHER | 1 | Oct 14, 2021 | clinicaltrials |
| NCT01644994 | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 47 | University of ZurichOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT05042557 | Real World Study of MPM in China | unknown | — | 500 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT00700336 | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) | completed | Phase 1 / Phase 2 | 69 | CanBas Co. Ltd.INDUSTRY | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03213301 | Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. | completed | Phase 2 | 42 | Swiss Cancer InstituteOTHER | 2 | Jul 14, 2021 | clinicaltrials |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | Health Pharma Professional ResearchOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04713761 | Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma | unknown | Phase 2 | 15 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jan 26, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jul 9, 2025source: clinicaltrials